Selected article for: "early phase and severe disease"
Author: Fanfan Zeng; Chan Dai; Pengcheng Cai; Jinbiao Wang; Lei Xu; Jianyu Li; Guoyun Hu; Lin Wang
Title: A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between gender.
  • Document date: 2020_3_27
    • ID: a1pa6g5c_31
    Snippet: Previous study reported a high severe rate and death rate in male patients relative to female patients [2] . However, the possible reason underlying was not referred. Here we reported that the production and dynamic of IgG antibody were different between male and female patients. In the early phase of the disease, the IgG antibody presented a stronger production in female patients. In the severe status, contrast with the male, SARS-CoV-2 IgG anti.....
    Document: Previous study reported a high severe rate and death rate in male patients relative to female patients [2] . However, the possible reason underlying was not referred. Here we reported that the production and dynamic of IgG antibody were different between male and female patients. In the early phase of the disease, the IgG antibody presented a stronger production in female patients. In the severe status, contrast with the male, SARS-CoV-2 IgG antibody in female tended to enrich in the high levels. The above two phenomena may be good reasons to explain the different outcomes between male and female COVID-19 patients. However, the exact mechanism contributing to this difference remains elusive and needs further investigation. At present, convalescent plasma was considered as a potential therapy for COVID-19 and now has been used in sever and critical patients in clinical [9] . Our study proposed that convalescent plasma should be used in advance especially for female patient with low IgG antibody for a long time to prevent the disease from progressing to severe and critical status, if the convalescent plasma is available. In addition, our study also supported that monitoring the SARS-CoV-2 antibody for routine examination maybe an efficient way to predict the progression of COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • convalescent plasma and different outcome: 1, 2
    • convalescent plasma and disease early phase: 1, 2, 3, 4, 5
    • convalescent plasma and disease prevent: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • convalescent plasma and early phase: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • convalescent plasma and elusive remain: 1, 2, 3
    • convalescent plasma and exact mechanism: 1
    • convalescent plasma and female IgG antibody: 1
    • convalescent plasma and female male patient: 1
    • death rate and different outcome: 1, 2
    • death rate and disease early phase: 1
    • death rate and disease prevent: 1, 2, 3, 4
    • death rate and early phase: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • death rate and female male patient: 1
    • death rate rate and disease prevent: 1
    • different outcome and disease early phase: 1, 2
    • different outcome and disease prevent: 1, 2
    • different outcome and early phase: 1, 2
    • different outcome and female IgG antibody: 1, 2
    • disease early phase and early phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25